Association of nonsteroidal anti-inflammatory drugs and aspirin use and the risk of head and neck cancers: a meta-analysis of observational studies
Metrics: PDF 838 views | HTML 1245 views | ?
Lanhua Tang1,*, Huabin Hu2,*, Huai Liu3,4, Chengzhu Jian5, Hui Wang3,4, Jin Huang1
1Department of Oncology, Xiangya Hospital of Central South University, Changsha, China
2Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
3Department of Radiotherapy, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
4Key Laboratory of Translational Radiation Oncology, Changsha, China
5Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
*Lanhua Tang and Huabin Hu contributed equally to this work
Jin Huang, email: firstname.lastname@example.org
Keywords: head and neck cancer, nonsteroidal anti-inflammatory drugs, aspirin, chemoprevention, meta-analysis
Received: May 02, 2016 Accepted: July 28, 2016 Published: August 12, 2016
Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have emerged as the potential chemopreventive agents for a number of cancer types, however, previous studies of head and neck cancers (HNC) have yielded inconclusive results. We performed a meta-analysis of observational studies to quantitatively assess the association between NSAIDs use and the risk for HNC.
Methods: We searched Pubmed, Embase, Google scholar, and Cochrane library for relevant studies that were published in any language, from January 1980 to April 2016. We pooled the odds ratio (OR) from individual studies and performed subgroup, heterogeneity, and publication bias analyses.
Results: A total of eleven studies (eight case-control studies and three cohort studies), involving 370,000 participants and 10,673 HNC cases contributed to this meta-analysis. The results of these studies suggested that neither use of overall NSAIDs (OR=0.95; 95% CI, 0.81-1.11), aspirin (OR=0.93; 95% CI, 0.79-1.10), nor nonsteroidal NSAIDs (OR=0.92; 95% CI, 0.76-1.10) were associated with HNC risk. Similar nonsteroidal results were observed when stratified by HNC sites, study design, sample size, and varied adjustment factors. However, we found significant protective effect of ibuprofen (OR=0.85; 95% CI, 0.72-0.99) and long-term aspirin use (≧5years) (OR=0.75; 95% CI, 0.65-0.85) on HNC risk, with low heterogeneity and publication bias.
Conclusions: Our meta-analysis results do not support the hypothesis that overall use of NSAIDs significant reduces the risk of HNC. Whereas, we cannot rule out a modest reduction in HNC risk associated with ibuprofen and long-term aspirin use.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.